Halozyme’s PEGylated adenosine deaminase 2 (PEG-ADA2) is an engineered human enzyme that targets and decreases the concentration of adenosine in the tumor microenvironment (TME). The adenosine pathway is a recognized immune checkpoint interaction and can be a key suppressor of immune cells in the TME.
In preclinical studies, PEG-ADA2 demonstrated tumor growth inhibition in certain colon, lung and pancreatic cancer models. Treatment with PEG-ADA2 resulted in an increase in infiltration of T cells and lowering of tumor adenosine levels. Halozyme scientists have also identified a potential biomarker for tumors that may respond to PEG-ADA2 therapy.
We plan to continue to study and characterize PEG-ADA2 with the goal of determining its suitability as a targeted therapy for clinical study.